Figure 3.
p16INK4a deficiency enhances rosiglitazone-induced pvAT formation in vivo: p16+/+ (n = 10) and p16−/− (n = 9) littermates were treated with rosiglitazone (15 mg/kg) for 5 weeks or vehicle and cardiac AT was stained for neutral lipids with Oil Red O (a). Scale bare represents 500 µm. Stained surface area was quantified at different locations from the valve area (b). Aortic perivascular AT gene expression of PPARγ (c), perilipin (d), F4/80 (e) and SCA-1 (f) was measured with qPCR, expressed as fold change relative to untreated controls (set at 1).
Data are represented as mean and SEM. Differences were assessed with either Student’s t-test or two-way ANOVA using Bonferroni post-test where appropriate. **p < 0.01 and *p < 0.05, ns = not significant.